Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.
about
Mechanisms underlying skin disorders induced by EGFR inhibitorsDifferent treatment strategies and molecular features between right-sided and left-sided colon cancersPrimary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort studyPTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational studyRight-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab.Nanoproteomic analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissueColorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients.A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: a Systematic Review and Meta-analysis.Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer.Current and future biomarkers in the treatment of colorectal cancer.Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis.Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy.Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis.The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis.Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.Left-sided primary tumor is a favorable prognostic factor for metastatic colorectal cancer patients receiving surgery.Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by ComprehenClinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials.Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer.Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice.
P2860
Q26745689-401772D1-B6F6-4069-B151-F9C31F134267Q26865322-3136E147-9D80-4D1F-9989-734BFD559C0AQ36028658-47156F13-B08D-43C7-AC01-486298742975Q36050773-018B4FAE-A0F3-47CE-B1FA-B7F998050A91Q36121090-1E147A9D-F90B-4B34-8A9D-D0A11CCFE03CQ36443572-BFE16B03-5975-4518-9BE5-F336BDC348F0Q37673704-15029215-8EB3-4319-8121-F841EB5F2218Q37675952-9EECE127-EDAA-46DD-8D3C-6B9771226774Q37735989-A57B2A69-CDCB-422C-8379-54C0DE43D352Q38634905-0CE26195-A10B-4760-9428-DE456151B8F6Q38767373-C59CEE58-8C1E-4B75-ABE8-F9F9AF5BD48CQ38775314-C683B9A4-B06F-4DA6-ACFF-2DD9B68CF29FQ38787244-FDE7D563-BD28-4C0D-9E78-662E407E0926Q38816712-385C07E0-4BCC-49E4-B8F3-0D759E65C1B2Q38847613-80AC4D4C-BA38-409F-90C8-789DF1C1E164Q39238657-B2F31777-6A8E-44A6-B6CC-9ED44F1F8479Q39703372-A0D88733-C649-4BFA-BCCC-2912ED6A9404Q40876056-62DFA245-160D-4F5C-97F0-6C4B51A094D9Q41149600-EE9A6E8A-91BB-443A-9A1D-C2C587F49DE1Q41593315-D1E2EFC6-BF0A-4EE3-88BE-24FD1B77D0EBQ41835603-C7E44D4D-0D02-46E0-8297-7B64958D7D6CQ43902845-DAA30CDF-33B2-45C5-8F57-15A2892EBF3AQ44355201-3FA4C80E-C939-4A3D-AA04-7493CEFDEC47Q46898020-05ECEEF5-7E43-4622-AC50-F00F46A0F36DQ47109685-F22AA0AB-5DD5-44E5-9612-CB0668A360DFQ47156794-C6235A34-54D8-444D-9EE2-0C641AC18569Q47163641-DC1F40E1-FE32-444F-B383-A7F5822E21BBQ47425132-01E1119C-D8FD-41FD-9CD6-C04098C4A460Q47675408-25606581-93BC-47D5-AE6E-2A927CB3E88DQ47744458-5C4682D9-1336-4245-AE20-0CE86B071548Q48139229-9EA62595-FA9B-4132-AEB7-861EC82C7F4AQ51307822-F8D9DFBC-8657-469D-9912-14B12A4D76A3Q54941578-4CFDE07E-4A81-4A1B-B8D3-9CB24BE5AC63Q55424327-81398DE5-B350-4BB7-B1E6-DFF319EFCC68
P2860
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@ast
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@en
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@nl
type
label
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@ast
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@en
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@nl
prefLabel
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@ast
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@en
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@nl
P2093
P2860
P921
P1476
Left-sided primary tumors are ...... sis of the AIO KRK-0104 trial.
@en
P2093
D P Modest
J C von Einem
L Fischer von Weikersthal
P2860
P2888
P304
P356
10.1007/S00432-014-1678-3
P577
2014-05-10T00:00:00Z